Combined Holdings of CRISPR Therapeutics (CRSP) - Updated Daily
TherapeuticsGene TherapyCAR-T Cell TherapyCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 2.45% | $3.66b |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 14 | 🇨🇭Switzerland |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
$70.01 - ARKG$62.32 - ARKK | 8.17% |
| Description | |
|---|---|
| CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. | |
| Website | |
| www.crisprtx.com |
Other ETFs That Hold CRSP
Research Notes and Commentary for CRSP
No Research Notes Found for CRSP